BioMarin Pharmaceutical Inc. (BMRN)
Symbol Info
Listed Symbol BMRN
Name BioMarin Pharmaceutical Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $1,470,356,000
Latest Fiscal EPS $-0.44
Price Info
21 Day Moving Average $68.0669
21 Day EMA $68.494400
50 Day Moving Average $71.7531
50 Day EMA $71.616910
200 Day EMA $81.119060
200 Day Moving Average 83.667380
52 Week High $105.45
52 Week Low $62.88
52 Week Change $-33.394302
Alpha -0.007284
Beta 1.2820
Standard Deviation 0.097268
R2 0.204865
Periods 60
Share Information
10 Day Average Volume 1,221,151
20 Day Average Volume 1,401,955
30 Day Average Volume 1,364,214
50 Day Average Volume 1,283,041
Outstanding Shares 179,462,759
Float Shares 177,770,668
Percent Float 99.06%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 1,037
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 15,661,333
Institute Holdings Percent -
Institute Sold Previous 3 Months 27,256,264
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 16
Insider Holdings Percent 0.90%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,692,091
Price Change
7 Day Price Change $1.7900009
7 Day Percent Change 2.66%
21 Day Price Change $0.8400040
21 Day Percent Change 1.23%
30 Day Price Change $-6.3499985
30 Day Percent Change -8.41%
Month To Date Price Change $1.7500
Month To Date Percent 2.60%
90 Day Price Change $-14.040001
90 Day Percent Change -16.88%
Quarter To Date $1.750000
Quarter To Date Percent 2.60%
180 Day Price Change $-14.010002
180 Day Percent Change -16.85%
200 Day Price Change $-20.279999
200 Day Percent Change -22.68%
Year To Date $-16
Year To Date Percent -18.79%
Profile
Description BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
Details
Issue Type CS
Market Cap $12,409,849,785
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 179,462,759
CEO Jean-Jacques Bienaime
Employees 2,849
Last Audit UE
Classification
CIK 0001048477
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 770 Lindaro Street
San Rafael, CA 94901
Website http://www.bmrn.com
Facisimile +1 415 382-7889
Telephone +1 415 506-6700
Email IR@BMRN.com
Key Ratios
Profitability
EBIT Margin -8.3
EBITDA Margin -1.8
Pre-Tax Profit Margin -24.1
Profit Margin Cont -8.71
Gross Margin 79.10
Profit Margin TOT -8.71
Income Statements
Revenue $1,120,709,000
Revenue Per Share $6.2448
Revenue 3 Years $6.12
Revenue 5 Years $14.27
Valuation Measures
PE Ratio -
Enterprise Value $12,214,016,956
Price To Sales 11.073213
Price To Free Cash -82.9
PE High Last 5 Years -
Price To Book 3.9
Price To Cash Flow 660.2
PE Low Last 5 Years -
Price To Tangible Book 5.0
Financial Strength
Total Debt To Equity 0.3
Int Coverage -4.1
Current Ratio 4.1
Leverage Ratio 1.4
Quick Ratio 2.5
Long Term Debt To Capital 0.22
Assets
Receivables Turnover 1.3
Invoice Turnover 0.50
Assets Turnover 0.10
Management Effectiveness
Return Assets -2.44
Return On Equity -3.77
Return On Capital -2.68
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
BMRN
BioMarin P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.